autoimmune pancreatitis
Conditions
Interventions
Prednisolone at a dose of 10mg/day is started. The dose is taperd by 2.5mg every 8-10 weeks until reaching 5mg/day. Maintenance therapy at a dose of 5 mg/day is continued.
Resuming or increasing pr
Sponsors
Department of Gastroenterology, University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Among patients who joined our clinical trial "Follow-up research on prognois of autoimmune pancreatitis after tapering steroid (UMIN000003798)", those who show serological relapse (defined as IgG>1600 mg/dl) during tapering steroid or after its cessation are enrolled in this study.
Exclusion criteria
Exclusion criteria: Patients who do not give their informed consent are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patients with AIP, who show serological relapse (defined as IgG>1600mg/dl) after their maintenance steroid dose is tapered or ceased, are enrolled in this study. They are divided into 2 groups, that is, 1) steroid resuming group, and 2) obsevation group. The main outcome is to clarify frequency and severity of pancreatic or extrapancreatic clinical relapse in each group within 3 years. | — |
Secondary
| Measure | Time frame |
|---|---|
| Morphological change of pancreas Pancreatic endocrine function Occurrence of malignancy Survival time | — |
Countries
Japan
Contacts
Public ContactKenji Hirano
University of Tokyo Clinical Research Support Center
Outcome results
None listed